Chronic Viral Infection

Inflammation triggers unsustainable immune response

Scientists at the University of Basel discovered a fundamental new mechanism explaining the inadequate immune defense against chronic viral infection. These results may open up new avenues for vaccine development.

In the course of an infection or upon vaccination, specialized cells of our immune system, so-called B cells, produce antibodies that bind viruses and inactivate them. In the context of chronic viral infections such as HIV or hepatitis C virus, however, antibody production by B cells is quantitatively inadequate and starts too late.

A team of scientists headed by Prof. Daniel Pinschewer at the Department of Biomedicine, University of Basel, reports that the inadequate antibody response to chronic viral diseases is due to the strong inflammatory reaction upon infection. While most pronounced at the onset of an infection, inflammation can persist for decades, especially in HIV/AIDS.

Hasty immune response lasts only short-term

Under the influence of inflammatory messengers, so called interferons, B cells produce as many antibodies as they possibly can. Unfortunately, this hasty response occurs at the expense of sustainability. B cells that turn on antibody production too quickly lose their potential to proliferate and die shortly thereafter. As a consequence, the immune response takes an impetuous start but subsides rapidly.

The scientists assume that this panic reaction of B cells reflects a mechanism ensuring an optimized response to acute life threatening infections. In the context of chronic infections, however, the battle is not decided within a matter of days, but rather only after months or years. Under these circumstances, the hasty reaction of our body seems inappropriate and may actually favor the virus.

Cornerstone for new vaccines

For viral diseases such as HIV or hepatitis C protective vaccines remain unavailable. The scientists are hopeful that the discovery of this fundamental mechanism may provide a basis to improve vaccination strategies against chronic viral diseases.


Original article
Fallet et al.: Interferon-driven deletion of antiviral B cells at the onset of chronic infection; Sci. Immunol. 1, eaah6817 (2016) | doi: 10.1126/sciimmunol.aah6817

Source: University of Basel

24.10.2016

More on the subject:

Related articles

Photo

News • ‘Reverse genetics’ system

New approach to norovirus vaccine and drug development

Researchers from Osaka have developed a simple and efficient system for understanding the functions of specific norovirus genes, providing new avenues for developing antivirals and vaccines.

Photo

News • From bird flu to pandemic

How Europe can prepare for avian flu spillover

In response to rising H5N1 avian influenza cases in Europe, a new framework aims to help countries detect and respond to spillover to humans – from enhanced surveillance to pandemic preparedness.

Photo

News • Cervical cancer prevention

HPV vaccine protects for a long time, study shows

More than a decade of protection against the human papillomavirus (HPV): a new study confirms the long-term effectiveness of the HPV vaccine to prevent development of cervical cancer and pre-cancer.

Related products

Subscribe to Newsletter